Dr. John Cush RheumNow
3 years 11 months ago
COVID-19 Arthropathy and Myalgia
An online survey of random COVID-19 infected persons shows that arthralgia and myalgia are common consequences to COVID-19 infection.
https://t.co/TbJvTRfsvk https://t.co/yuLN5p5ZAn
The California Lupus Surveillance Project has longitudinally followed included systemic lupus erythematosus (SLE) cases and shown that overall, the leading cause of death was cardiovascular disease (CVD), followed by rheumatic disease and hematologic/oncologic conditions.
Analysis of data from a Czech nationwide registry of psoriatic patients receiving biologic or targeted therapies (BIOREP) has shown a high success rate when switching between specific IL-17 inhibitors.
Dr. John Cush RheumNow
3 years 11 months ago
Dr. Alfonse Masi donates $1.2 Million to establish the Masi endowed chair in Medicine at the University of Illinois College of Medicine, Peoria. Dr. Masi is a giant clinician, researcher, epidemiologist in Rheum w/ > 220 Pubs & Yrs service to the ACR https://t.co/MbCFVZyNs1 https://t.co/LQ9D0ypA53
Dr. John Cush RheumNow
3 years 11 months ago
2022 Lasker Award Winners
Widely regarded as America’s top biomedical research prize since its creation more than 75 years ago by Mary and Albert Lasker, the Lasker Awards carry an honorarium of $250,000 for each category.
https://t.co/wBIGMR6lH7 https://t.co/t9HUECimys
Dr. John Cush RheumNow
3 years 11 months ago
Opioid Crisis Costs USA $1.5 Trillion
Reuters has reported the results of a Congressional report showing the economic toll of the opioid addiction and overdose crisis on the United States reached nearly $1.5 trillion in 2020 alone and is likely to grow.
https://t.co/Fwk6jDdtiD https://t.co/91d26iEZts
Dr. John Cush RheumNow
3 years 11 months ago
This week it's the great and not-so-great on gout, chondrocalcinosis, osteoporosis and misdiagnosis. We are good at many of those things - what's not so great? Let's review the news and journal reports from the past week on RheumNow.
https://t.co/30Ih3xj22t https://t.co/YznOuGg5B2
Dr. John Cush RheumNow
3 years 11 months ago
2 open-label reports of JAK inhibitors in Systemic sclerosis (SSc) - 59 SSc pts: significant decr in mRSS in 88%. 28/29 w/ ILD had no progression. Overall responses better in treatment naïve SSc patients. 20% had side-effects. More studies needed https://t.co/PPAHocDWBj https://t.co/hZDGOF6r9k
Dr. John Cush RheumNow
3 years 11 months ago
Five Senses of Medicine - nice graphic download on Clinical Skils (from Annals of Internal Medicine) https://t.co/8RNpqovtVP https://t.co/FkOSZCtv8c
Dr. John Cush RheumNow
3 years 11 months ago
Efficacy and Safety of JAK Inhibitors in Psoriatic Disease
There is a growing body of evidence demonstrating efficacy and safety of JAK inhibitors in patients with moderate-to-severe PSO and PsA, according to a systematic review in BMC Rheumatology.
https://t.co/8Y4V1jUlzo https://t.co/eFqknUfGat
Dr. John Cush RheumNow
3 years 11 months ago
Study of 67 OA TKR pts looked for CPPD - defined as "appears as linear/punctate opacities w/in cartilage, synovium, Jt capsule or tendons/entheses". Xrays had specificity of 92%, sensitivity 54%, PPV 88%, NPV 66% (needs to be distinguished from BCP) https://t.co/i0ZagblzPZ https://t.co/CiusWPzjrK
Dr. John Cush RheumNow
3 years 11 months ago
Are We Overcautious With TNF Inhibitors in Pregnancy?
What may seem like a prudent approach to treatment of IBD in pregnant women actually represents an overabundance of caution, suggested researchers who found no increased risk from TNF inhibitors.
https://t.co/gYqJDBHTBQ https://t.co/aBXl49wJzM
Dr. John Cush RheumNow
3 years 11 months ago
Long term results of KEEPsAKE 1 and 2, RCTS of SKYRIZI (IL-23 inhibitor) in active #PsA pts were presented at EADV mtg in Milan. At wk 100, showed more than half of PsA patients achieved PASI 90 & ACR 20 responses. https://t.co/ZJsR0R5WNW https://t.co/2GU5aaSwDZ
Dr. John Cush RheumNow
3 years 11 months ago
IL-18 is a proinflammatory cytokine involved in innate &adaptive immune responses. IL-18 is a key mediator in autoinflammatory diseases, MAS, Still’s disease. Serum IL-18 levels may be useful in diagnosis and monitoring of disease activity https://t.co/P8ecLAtNx5 https://t.co/3mo1vcYKUr
Dr. John Cush RheumNow
3 years 11 months ago
Cancer Risk with Scleroderma
Spanish Scleroderma Registry examined a large cohort of systemic sclerosis (SSc) patients showing an increased cancer risk, especially breast, lung, hematologic and colorectal cancer.
https://t.co/2sCI6AejRn https://t.co/estX9D39tZ
